ArticleScience translational medicine2019
Pharmacological enhancement of
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
14.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- Engineered tissues and strategies to overcome challenges in drug development.Advanced drug delivery reviews · 2020Pooled it
- Abnormal KCC2 expression and function in a mouse model of epilepsy and tuberous sclerosis complex.Epilepsia · 2026Article
- Role of GABAMolecular biology reports · 2026Article
- KCC2 activation during postnatal development alleviates long-term deficits in CDKL5-deficient mice.Experimental & molecular medicine · 2026Article
- The CaInternational journal of molecular sciences · 2025Review
- AAV9-mediated KCC2 upregulation enhances functional recovery following cervical spinal cord injury.Communications biology · 2025Article
- KCC2 enhancers normalize reflex responses and improve locomotor function after chronic spinal cord injury.The Journal of physiology · 2025Article
- Potentiation of group III metabotropic glutamate receptors positively affects neurophysiological features in a mouse model of Rett syndrome.The Journal of pharmacology and experimental therapeutics · 2025Article
- Visualizing the Cellular and Subcellular Distribution of Fms-like Tyrosine Kinase 3 (Flt3) and Other Neuronal Proteins Using Alkaline Phosphatase (AP) Immunolabeling.International journal of molecular sciences · 2025Article
- Neuroimmune-competent human brain organoid model of diffuse midline glioma.Neuro-oncology · 2025Article
- Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024).Exploration of drug science · 2025Article
- Altered GABAergic signaling and chloride homeostasis in eye movement circuits during late neurodevelopment: implications for Alzheimer's disease therapy.Frontiers in pharmacology · 2025Review
- Identification of novel neuroprotectants against vincristine-induced neurotoxicity in iPSC-derived neurons.Cellular and molecular life sciences : CMLS · 2024Article
- Human-Induced Pluripotent Stem Cell (iPSC)-Derived GABAergic Neuron Differentiation in Bipolar Disorder.Cells · 2024Article
- Identification of novel neuroprotectants against vincristine-induced neurotoxicity in iPSC-derived neurons.Research square · 2024Article
- Heterogeneous subpopulations of GABAiScience · 2024Article
- Neuronal KActa pharmacologica Sinica · 2024Review
- Development of KCC2 therapeutics to treat neurological disorders.Frontiers in molecular neuroscience · 2024Article
- Therapeutic potential for KCC2-targeted neurological diseases.The Japanese dental science review · 2023Review
- Rett and Rett-related disorders: Common mechanisms for shared symptoms?Experimental biology and medicine (Maywood, N.J.) · 2023Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 5 institutions in 2 countries.
Xin TangWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.ORCID 0000-0003-2883-2610
Jesse DrotarWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Keji LiPicower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-0737-2558
Cullen D ClairmontWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.ORCID 0000-0002-9672-2205
Anna Sophie BrummFrancis Crick Institute, London NW1 1AT, UK .
Austin J SullinsPicower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-3276-0472
Hao WuFulcrum Therapeutics, Cambridge, MA 02139, USA.
Xiaoxiao Shawn LiuWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Jinhua WangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Nathanael S GrayDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Mriganka SurPicower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-2442-5671
Rudolf JaenischWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA. jaenisch@wi.mit.edu.ORCID 0000-0002-2540-7099
Whitehead Institute for Biomedical Research · USMassachusetts Institute of Technology · USHarvard University · USFulcrum Therapeutics (United States) · USThe Francis Crick Institute · GB
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9MGENOMIC IMPRINTING AND THE CLONING OF MICER37CA084198 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI JAENISCH, RUDOLF · 2000 to 2008
$9.2MIn Vitro Reprogramming of Somatic Cells into Pluripotent ES-like CellsR37HD045022 · NICHD · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI JAENISCH, RUDOLF · 2009 to 2017
$7.5MTranscriptional condensates, epigenetic editing and Rett SyndromeR01MH104610 · NIMH · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI JAENISCH, RUDOLF, YOUNG, RICHARD · 2014 to 2023
$7.4MMicroRNA mechanisms of Rett SyndromeR01MH085802 · NIMH · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SUR, MRIGANKA · 2010 to 2025
$6.2MAn iPSC based platform for functionally assessing genetic and environmental riskR01NS088538 · NINDS · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI JAENISCH, RUDOLF, MYERS, RICHARD H · 2014 to 2018
$5.0MNuclear Cloning and the Reprogramming of the GenomeR01HD045022 · NICHD · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI JAENISCH, RUDOLF · 2003 to 2008
$4.7MNCI NIH HHS P30 CA014051NCI NIH HHS R37 CA084198NICHD NIH HHS R01 HD045022NICHD NIH HHS R37 HD045022NIMH NIH HHS R01 MH085802NIMH NIH HHS R01 MH104610NINDS NIH HHS R01 NS088538
Abstract
Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the methyl CpG binding protein 2 (
Indexed as
AnilidesAnimalsBenzimidazolesClustered Regularly Interspaced Short Palindromic RepeatsElectroretinographyEnzyme InhibitorsFemalefms-Like Tyrosine Kinase 3Glycogen Synthase Kinase 3 betaHumansIndazolesK Cl- CotransportersMaleMethyl-CpG-Binding Protein 2MiceNeuronsAnilidesBenzimidazolescabozantinibcrenolanibEnzyme Inhibitorsfms-Like Tyrosine Kinase 3Glycogen Synthase Kinase 3 betaIndazolesK Cl- CotransportersKW 2449Mecp2 protein, mouseMethyl-CpG-Binding Protein 2PiperazinesPiperidinesPyridinesPyrimidinesPyrrolesSirtuin 1SLC12A5 protein, humanSunitinibSymportersTWS 119
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.